2025 Annual Meeting | Industry Therapeutic Update from Alexion, AstraZeneca Rare Disease: Evolving our understanding of a complement inhibitor in anti-AChR antibody-positive gMG: Expert panel reviews pivotal study and long-term data (164 weeks total)

Date Wednesday 04/09/25

Time 11:45 AM - 12:45 PM PDT Add To Calendar

Location San Diego Convention Center | 6B

Session Format This program will be presented in-person only

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Industry Therapeutic Update

Director(s) Christopher A. Scheiner, MD, PhD

Topic(s) General Neurology, Autoimmune Neurology

Learning Objectives Engage with leading experts as they review 164-week pivotal study and OLE data on a complement inhibitor and discuss practical approaches to initiating therapy in real-world settings. Hear patient case examples showcasing how collaborative care helps with the initiation process of a treatment for adult patients living with anti-AChR antibody-positive gMG.
This program is NOT accredited for continuing education by any organization. Additionally, Industry Therapeutic Updates program content and the views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an official part of the 2025 AAN Annual Meeting education or scientific programs, nor are they endorsed by the AAN. The AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.

CME Available No CME available

Program Materials

Event Timeline
11:45 AM - 12:45 PM PDT	Speaker	Industry Therapeutic Update from Alexion, AstraZeneca Rare Disease: Evolving our understanding of a complement inhibitor in anti-AChR antibody-positive gMG: Expert panel reviews pivotal study and long-term data (164 weeks total)\

Faculty Disclosures
Christopher A. Scheiner, MD, PhD	Dr. Scheiner has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion Pharmaceuticals . Dr. Scheiner has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for CSL Behring . Dr. Scheiner has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx Pharmaceuticals. Dr. Scheiner has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for CSL Behring . Dr. Scheiner has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Alexion Pharmaceuticals . The institution of Dr. Scheiner has received research support from Alexion Pharmaceuticals .

��ɫ��

��ɫ��